StockMirror — Stock Screener

RAINBOW Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Rainbow Children's Medicare delivered a landmark FY26 with highest-ever bed additions (~500) and Q4 revenue of INR 460 Cr (24% YoY growth). Full-year revenue grew 12% to INR 1,703 Cr, below potential 18-20% due to weak seasonality and geopolitical headwinds. Management targets 20% growth in FY27, driven by maturing new hospitals, fertility expansion (25% YoY), and improving occupancy. Strong balance sheet (zero debt, INR 594 Cr cash) funds ~900-bed expansion pipeline (including Gurugram, Pune, Coimbatore) valued at ~INR 700-850 Cr capex over 2 years. Margins remain healthy (EBITDA 32%, PAT 16.6% for FY26). Key risks: seasonality dependence, execution of large greenfield projects, and international patient headwinds.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management explicitly targets 20% revenue growth 'while maintaining margins'. CEO stated: 'driving aspirational yet achievable growth of 20% in the current year while maintaining margins.' CFO confirmed balance sheet strength to fund both organic and inorganic growth without compromising margins.

About Rainbow Children's Medicare Limited

Rainbow Children's Medicare Limited (RAINBOW) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More